In the April 7, 2015, Federal Register, FDA announced it has issued a priority review voucher for Cholbam (cholic acid), pursuant to authority provided in the Food and Drug Administration Safety and Innovation Act. Cholbam is a bile acid indicated for the treatment of bile acid synthesis disorders and other peroxisomal disorders.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.